Bufacord Caution For Usage

Incompatibilities: In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products except those mentioned as follows.
Do not use polycarbonate syringes with Busulfan.
Special precautions for disposal and other handling: Preparation of Busulfan: Procedures for proper handling and disposal of anticancer medicinal products should be considered.
All transfer procedures require strict adherence to aseptic techniques, preferably employing a vertical laminar flow safety hood.
As with other cytotoxic compounds, caution should be exercised in handling and preparing the busulfan solution: The use of gloves and protective clothing is recommended.
If the concentrate or diluted busulfan solution contacts the skin or mucosa, wash them thoroughly with water immediately.
Calculation of the quantity of Busulfan to be diluted and of the diluent: Busulfan must be diluted prior to use with either sodium chloride 9 mg/mL (0.9%) solution for injection or glucose solution for injection 5%.
The quantity of the diluent must be 10 times the volume of Busulfan ensuring the final concentration of busulfan remains at approximately 0.5 mg/mL. By example: The amount of Busulfan and diluent to be administered would be calculated as follows: For a patient with a Y kg body weight: Quantity of Busulfan: See eqaution.

Click on icon to see table/diagram/image

Quantity of diluent: (A mL Busulfan) x (10) = B mL of diluent
To prepare the final solution for infusion, add (A) mL of Busulfan to (B) mL of diluent (sodium chloride 9 mg/mL (0.9%) solution for injection or glucose solution for injection 5%).
Preparation of the solution for infusion: Busulfan must be prepared by a healthcare professional using sterile transfer techniques. Using a non polycarbonate syringe fitted with a needle: The calculated volume of Busulfan must be removed from the vial.
The contents of the syringe must be dispensed into an intravenous bag (or syringe) which already contains the calculated amount of the selected diluent. Busulfan must always be added to the diluent, not the diluent to Busulfan.
Busulfan must not be put into an intravenous bag that does not contain sodium chloride 9 mg/mL (0.9%) solution for injection or glucose solution for injection 5%.
The diluted solution must be mixed thoroughly by inverting several times.
After dilution, 1 mL of solution for infusion contains 0.5 mg of busulfan. Diluted Busulfan is a clear colourless solution.
Instructions for use: Prior to and following each infusion, flush the indwelling catheter line with approximately 5 mL of sodium chloride 9 mg/mL (0.9%) solution for injection or glucose (5%) solution for injection.
The residual medicinal product must not be flushed in the administration tubing as rapid infusion of busulfan has not been tested and is not recommended.
The entire prescribed Busulfan dose should be delivered over two or three hours depending of the conditioning regimen.
Small volumes may be administered over 2 hours using electric syringes. In this case infusion sets with minimal priming space should be used (i.e. 0.3-0.6 mL), primed with medicinal product solution prior to beginning the actual Busulfan infusion and then flushed with sodium chloride 9 mg/mL (0.9%) solution for injection or glucose (5%) solution for injection.
Busulfan must not be infused concomitantly with another intravenous solution. Polycarbonate syringes must not be used with Busulfan.
For single use only. Only a clear solution without any particles should be used.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements for cytotoxic medicinal products.